. AlvingBM: A. How I treat heparin-induced thrombocytopenia and thrombosis. Blood. 2003101(1):31–7, 2003.
2.
. AndersonFAJr.HirshJWhiteKFitzgeraldRHJr.: Temporal trends in preventionof venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry. Chest.124:349S–356S, 2003.
3.
. ArepallyGCinesDB: Pathogenesis of heparin-induced thrombocytopenia and thrombosis. Autoimmun. Rev.1:125–132, 2002.
4.
. ArepallyGMOrtelTL: Clinical practice. Heparin-induced thrombocytopenia. N Engl. J. Med.355:809–817, 2006.
5.
. ArthurCKGrantSJBMurrayWK: Heparin-associated acute adrenal insufficiency. Aust. N Z J Med.15:454–5, 1985.
6.
. BairdRAConveryR: Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia. J Bone Joint Surg. Am.59:1061–1064, 1977.
7.
. BarberFABurtonWCGuyerR: The heparin-induced thrombocytopenia and thrombosis syndrome. Report of a case. J Bone Joint Surg. Am.69:935–937, 1987.
8.
. BauerTLArepallyGKonkleBA: Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation.95:1242–6, 1997.
9.
. BicalhoPSHozackWJRothmanRHEngK: Treatment of early symptomatic pulmonary embolism after total joint arthroplasty. J. Arthroplasty.11:522–524, 1996.
10.
. BlankMShoenfeldYTavorS: Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int. Immunol.14:121–9, 2002.
11.
. CapriniJA: Thrombosis risk assessment as a guide to quality patient care. Dis. Mon.51:70–78, 2005.
12.
. CapriniJATapsonVFHyersTM: Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J. Vasc. Surg.42:726–733, 2005.
13.
. CardenasGADeitcherSR: Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia. Mayo Clin. Proc.80:491–3, 2005.
14.
. ChongBHGallusASCadeJF: Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb. Haemost.86:1170–1175, 2001.
15.
. ChongBHIsmailFCadeJ: Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood. May 1;73(6):1592–6, 1989.
16.
. CinesDBRauovaLArepallyG: Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J. Clin. Apher.22:31–6, 2007.
17.
. ColwellCWJr.SpiroTETrowbridgeAA: Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg. Am.76:3–14, 1994.
18.
. DavorenAAsterRH: Heparin-induced thrombocytopenia and thrombosis. Am. J Hematol.81:36–44, 2006.
19.
. DahlOECapriniJAColwellCWJr.: Fatal vascular outcomes following major orthopedic surgery. Thromb. Haemost.93(5):860–6, 2005.
. DenysBStoveVPhillippeJDevreeseK: A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin induced thrombocytopenia. Thromb Res. DOI:10.1016/j.thrombres.2008.04.020. In press, June 2008.
22.
. FabrisFLuzzattoGSoiniB: Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern. Med.252:149–154, 2002.
. FreedmanKBBrookenthalKRFitzgeraldRHJr.WilliamsSLonnerJH: A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg.82-A(7):929–38, 2000.
25.
. FriedmanRJGallusASCushnerFDFitzgeraldGAndersonFAJr.: Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Current medical research and opinion.24:87–97, 2008.
26.
. WarkentinTEGreinacherAKosterALincoffAM: Treatment and prevention of heparin induced thrombocytopenia: American College of Chest Physicians evidence based clinical practice guidelines (8th Edition). Chest.133(6 Suppl):340–380, 2008.
27.
. GeertsWHPineoGFHeitJA: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest.126:338S–400S, 2004.
28.
. GirolamiBPrandoniPStefaniPM: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood.101:2955–9, 2003.
29.
. GreinacherAAmiralJDummelV: Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion.34(5):381–5, 1994.
30.
. GreinacherAEichlerPLietzTWarkentinTE: Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood.106:2921–2, 2005.
31.
. GreinacherAEichlerPLubenowNKwasnyHLuzM: Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood.96(3):846–51, 2000.
32.
. GreinacherAFarnerBKrollH: Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost.94:132–135, 2005.
33.
. GreinacherAJanssensUBergG: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation.100:587–593, 1999.
34.
. GreinacherAVolpelHJanssensU: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation.99:73–80, 1999.
35.
. GreinacherAWarkentinTE: Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res.118(2):165–76, 2006.
36.
. GruelYPouplardCNguyenP: Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br. J Haematol.121(5):786–92, 2003.
37.
. HanslowSSGrujicLSlaterHKChenD: Thromboembolic disease after foot and ankle surgery. Foot Ankle Int.27:693–695, 2006.
38.
. HarenbergJHuhleGGieseC: Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia. Br. J Haematol.109:182–6, 2000.
39.
. HirshJHeddleNKeltonJG: Treatment of heparin-induced thrombocytopenia: a critical review. Arch. Intern Med.164(4):361–9, 2004.
40.
. HirshJRaschkeR: Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest.126:188S–203S, 2004.
41.
. HirshJWarkentinTEShaughnessySG: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest.119:64S–94S, 2001.
42.
. HongAPCookDJSigouinCSWarkentinTE: Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood.101(8):3049–51, 2003.
43.
. KejariwalD: Heparin-induced thrombocytopenia: a complication of thromboprophylaxis. J Bone Joint Surg. Br.88:392–393, 2006.
44.
. KeltonJG: The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest.127:9S–20S, 2005.
45.
. KiserTHFishDN: Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy.26(4):452–60, 2006.
46.
. KodityalSNguyenPHKodityalA: Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med.21:86, 2006.
47.
. LaceyJVPennerJA: Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost.3:160–74, 1977.
48.
. LamFHussainSLiP: Limb loss following the use of heparin. A lesson to be remembered. J Bone Joint Surg. Br.84:588–589, 2002.
49.
. LaMonteMPBrownPMHurstingMJ: Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit. Care Med.2004; 32:976–80, 2004.
50.
. LapidusLJRosforsSPonzerS: Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. J Orthop. Trauma.21:52–57, 2007.
51.
. LasterJLNicholsWKSilverD: Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies. Arch Intern. Med.149:2285–2287, 1989.
. LevineRLMcCollumDHurstingMJ: How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?Chest.130(3):681–7, 2006.
54.
. LewisBEWallisDEBerkowitzSD: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation.103:1838–1843, 2001.
55.
. LewisBEWallisDELeyaFHurstingMJKeltonJG: Argatroban-915 Investigators. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest.129:1407–56, 2006.
56.
. LewisBEWallisDELeyaFHurstingMJKeltonJG: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern. Med.163:1849–1856, 2003.
57.
. LilikakisAKPapapolychroniouTMacherasGMichelinakisE: Thrombocytopenia and intra-cerebral complications associated with low-molecular-weight heparin treatment in patients undergoing total hip replacement. A report of two cases. J Bone Joint Surg. Am.88:634–638, 2006.
58.
. Lindhoff-LastEWenningBSteinM: Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopenia. Clin. Appl. Thromb Hemost.8:347–352, 2002.
59.
. LoGKJuhlDWarkentinTE: Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost.4:759–765, 2006.
60.
. LubenowNEichlerPLietzTFarnerBGreinacherA: Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood.104:3072–3077, 2004.
61.
. LubenowNEichlerPLietzTGreinacherA: Lepirudin in patients with heparin induced thrombocytopenia – results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J. Thromb Haemost.3:2428–2436, 2005.
62.
. LubenowNKempfREichnerA: Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest.122:37–42, 2002.
63.
. MagnaniHN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost.70(4):554–61, 1993.
64.
. MagnaniHNGallusA: Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost.95:967–981, 2006.
65.
. MandtPRRobinsonCASarnoffRBColwellCWJr: Heparin-associated thrombocytopenia with venous thrombosis. A case report. J Bone Joint Surg. Am.67:1123–1124, 1985.
66.
. MarkovichGDRussellJMGagneP: Antibody-induced arterial thromboembolism resulting in amputation after total knee arthroplasty. J. Arthroplasty.12:350–352, 1997.
67.
. MartelNLeeJWellsPS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood.106:2710–2715, 2005.
68.
. MenajovskyLB: Heparin-induced thrombocytopenia: clinical manifestations and management strategies. Am J Med.118Suppl 8A:21S–30S, 2005.
69.
. MicheliLJ: Thromboembolic complications of cast immobilization for injuries of the lower extremities. Clin. Orthop. Relat. Res.191–195, 1975.
70.
. MizelMSTempleHTMichelsonJD: Thromboembolism after foot and ankle surgery. A multicenter study. Clin. Orthop. Relat. Res.180–185, 1998.
71.
. MooreJRWeilandAJ: Heparin-induced thromboembolism: a case report. J. Hand Surg. [Am].4:382–385, 1979.
72.
. MuslimaniAARicaurteBDawHA: Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol.82:652–5, 2007.
73.
. NapolitanoLMWarkentinTEAlmahameedANasrawaySA: Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit. Care Med.34:2898–2911, 2006.
74.
. NewmanPMChongBH: Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood.96:182–7, 2000.
75.
. PapadopoulosSFlynnJDLewisDA: Fondaparinux as a treatment option for heparin induced thrombocytopenia. Pharmacotherapy.27:921–926, 2007.
76.
. PatelVPBongMDiCesarePE: Heparin Induced Thrombocytopenia and Thrombosis. Am J Orthopedics36(5):255–260, 2007.
77.
. PattersonBMMarchandRRanawatC: Complications of heparin therapy after total joint arthroplasty. J Bone Joint Surg. Am.71:1130–1134, 1989.
78.
. PittoRPHamerHHeiss-DunlopWKuehleJ: Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg. Br.86:639–642, 2004.
79.
. PlanèsASamamaMMLensingAW: Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost.81:22–5, 1999.
80.
. PötzschBKlövekornWPMadlenerK: Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J. Med.17343(7):515, 2000.
81.
. PouplardCAmiralJBorgJY: Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol.111(5):700–6, 1999.
82.
. PouplardCIochmannSRenardB: Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood.97:3300–2, 2001.
83.
. PouplardCGueretPFourassierMTernisienCReginaSGruelY: Prospective evaluation of the ‘4Ts’ scope and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin induced thrombocytopenia. J Thrmob. Haemost.5(7):1373–9, 2007.
84.
. RauovaLZhaiLKowalskaMA: Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood.107:2346–53, 2006.
85.
. RiceLAttishaWKDrexlerAFrancisJL: Delayed-onset heparin-induced thrombocytopenia. Ann. Intern. Med.136:210–215, 2002.
86.
. SchiffRLKahnSRShrierI: Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest.128:3364–3371, 2005.
87.
. SchenkSEl-BanayosyAMorshuisM: IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb. Haemost.5:235–41, 2007.
88.
. SellengKWarkentinTEGreinacherA: Heparin-induced thrombocytopenia in intensive care patients. Crit. Care Med.35(4):1165–76, 2007.
89.
. SmytheMAWarkentinTEStephensJLZakalikDMattsonJC: Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol.71:50–52, 2002.
90.
. SmytheMAKoerberJMMattsonJC: The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest.131:1644–9, 2007.
91.
. SolisGSaxbyT: Incidence of DVT following surgery of the foot and ankle. Foot Ankle Int.23:411–414, 2002.
92.
. StantonPEJr.EvansJRLefemineAA: White clot syndrome. South Med. J.81(5):616–20, 1988.
93.
. StriblingWKSlaughterTFHouleTTSaneDC: Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J.153(6):900–6, 2007.
94.
. SuvarnaSEspinasseBQiR: Determinants of PF4/heparin immunogenicity. Blood.110:4253–60, 2007.
95.
. TardyBLecompteTBoelhenF: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood.108:1492–96, 2006.
96.
. TaylorLMSmithKM: The paradox of heparin-induced thrombocytopenia: future anticoagulation. Orthopedics.28:651–654, 2005.
97.
. TaylorLMSmithKM: The paradox of heparin-induced thrombocytopenia: the initial management. Orthopedics.28:559–562, 2005.
98.
. VermaAKLevineMShalanskySJCarterCJKeltonJG: Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy.23:745–53, 2003.
99.
. WallisDEWorkmanDLLewisBE: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J. Med.106:629–35, 1999.
100.
. WangFWeraGKnoblichGOChouLB: Pulmonary embolism following operative treatment of ankle fractures: a report of three cases and review of the literature. Foot Ankle Int.23:406–410, 2002.
101.
. WarkentinTE: Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol.35:9–25, 1998.
102.
. WarkentinTE: Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev. Med.50:129–147, 1999.
103.
. WarkentinTE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch. Pathol Lab. Med.126:1415–1423, 2002.
104.
. WarkentinTE: Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol.121:535–555, 2003.
105.
. WarkentinTE: Think of HIT. Hematology Am Soc Hematol Educ Program.408–414, 2006.
106.
. WarkentinTECookRJMarderVJ: Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood.106:3791–3796, 2005.
107.
. WarkentinTEEikelboomJW: Who Is (still) getting HIT?Chest.131:1620–2, 2007.
108.
. WarkentinTEElavathilLJHaywardCP: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med.127:804–812, 1997.
109.
. WarkentinTEGreinacherA: Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest.126:311S–337S, 2004.
110.
. WarkentinTEHirteHWAndersonDR: Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med.97:489–91, 1994.
111.
. WarkentinTEKeltonJG: A 14-year study of heparin-induced thrombocytopenia. Am J Med.101:502–507, 1996.
112.
. WarkentinTEKeltonJG: Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern. Med.135:502–506, 2001.
113.
. WarkentinTEKeltonJG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med.344:1286–1292, 2001.
114.
. WarkentinTELevineMNHirshJ: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med.332:1330–1335, 1995.
115.
. WarkentinTEMaurerBTAsterRH: Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med.356:2653–2655; discussion 2653–2655, 2007.
116.
. WarkentinTERobertsRSHirshJKeltonJG: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern. Med.163:2518–2524, 2003.
117.
. WarkentinTESheppardJAHorsewoodP: Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood.96:1703–1708, 2000.
118.
. WarkentinTESheppardJASigouinCS: Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood.108:2937–41, 2006.
. WatsonHGKeelingDM: BCSH Taskforce in Haemostasis and Thrombosis. The management of heparin-induced thrombocytopenia. Br J Haematol.135(2):269, 2006.
121.
. WhitePWSaddJRNenselRE: Thrombotic complications of heparin therapy: including six cases of heparin-induced skin necrosis. Ann Surg.190(5):595–608, 1979.
122.
. WolfJMDiGiovanniCW: A survey of 702 orthopedic surgeons regarding DVT prophylaxis in foot and ankle trauma surgery. Orthopedics.27:504–508, 2004.
